GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Aug 8, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Aug 8, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-repurchase, corporate-action
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on August 8, 2025, that it has purchased a number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for large public companies.
Key Players & Entities
- GSK plc (company) — The company making the share purchase.
- Merrill Lynch International (company) — The corporate stockbroker acting on behalf of GSK plc.
- August 8, 2025 (date) — The date of the announcement and transaction.
FAQ
What is the total number of GSK plc ordinary shares purchased?
The filing states that GSK plc has purchased 'the following number of the Company's ordinary shares' but does not specify the exact quantity in the provided text.
What is the total dollar amount spent on the share repurchase?
The filing does not disclose the total dollar amount of the share repurchase.
When did the share repurchase transaction take place?
The announcement was made on August 8, 2025, and the transaction occurred on or around this date.
Who is acting as GSK plc's corporate stockbroker for this transaction?
Merrill Lynch International is acting as GSK plc's corporate stockbroker.
What is the par value of GSK plc's ordinary shares?
The ordinary shares are of 31¼ pence each.
Filing Stats: 2,912 words · 12 min read · ~10 pages · Grade level 3.6 · Accepted 2025-08-08 06:31:29
Filing Documents
- a4942u.htm (6-K) — 7312KB
- 0001654954-25-009238.txt ( ) — 7313KB
From the Filing
IN OWN SHARES a4942u   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of August 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .       Transaction in own shares   GSK plc (the " Company ") announces today   acting through its corporate stockbroker, Merrill Lynch International (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.     Date of purchase:   07 August 2025   Aggregate number of ordinary shares of  31¼  pence each purchased:   502,466   Lowest price paid per share (GBp):   1,361.00p   Highest price paid per share (GBp):   1,385.50p   Volume-weighted average price paid per share (GBp):   1,376.94p     The purchased shares will be held as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 21,410,644 ordinary shares.   Following the above purchase, the Company will hold 239,545,027 ordinary shares in treasury and have 4,075,843,458 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,075,843,458. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is   5.88 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases   Shares purchased:      GSK plc (ISIN: GB00BN7SWP63)   Date of purchases:      07 August 2025   Investment firm:        Merrill Lynch International   Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share) (GBp)   Lowest price paid (per ordinary share) (GBp)   Volume weighted average price paid (per ordinary share) (GBp)   London Stock Exchange (XLON)   502,466   1,385.50p   1,361.00p   1,376.94p   CBOE ( CHIX)   0   -   -   -   CBOE ( BATE)   0   -   -   -     Individual transactions:   Number ofShares   Price per Share (GBp)   Tradingvenue   Date oftransaction   Time oftransaction   Transaction reference number   22   1,366.00    XLON   07-Aug-2025   08:00:12   0XL0617000000000ARCLAV   29   1,366.00    XLON   07-Aug-2025   08:00:12   0XL0611000000000ARCLAD   30   1,366.00    XLON   07-Aug-2025   08:00:12   0XL0670000000000ARCL7A   30   1,366.00    XLON   07-Aug-2025   08:00:12   0XL06D0000000000ARCL8B   31   1,366.00    XLON   07-Aug-2025   08:00:12   0XL0610000000000ARCL09   31   1,366.00    XLON   07-Aug-2025   08:00:12   0XL0614000000000ARCLA9   31   1,366.00    XLON   07-Aug-2025   08:00:12   0XL0640000000000ARCL6V   32   1,366.00    XLON   07-Aug-2025   08:00:12   0XL0614000000000ARCLAA